Tag:

Roche

Latest Headlines

Latest Headlines

Roche, Amgen, Novo top the ranks in biologics sales, with AbbVie, Sanofi close behind

The world's top sellers of the world's top biologic meds haven't changed much in the last few years. Ranked by 2014 sales, it's your usual suspects--Roche, Amgen, Novo Nordisk, AbbVie. But as PMLiVE notes in its annual ranking, times are a-changing.

Roche charges ahead with diagnostics R&D after sealing Foundation deal

Roche is not wasting any time after sealing its $1.2 billion deal for Foundation Medicine, charging full speed ahead with the companies' planned cancer R&D collaboration to generate growth in the coming year.

FDA, industry scrambling to clarify or design new regs covering lab-developed tests

Science is rapidly shaping the landscape of the diagnostics industry, from the research into genetics and new materials like graphene, to the regulatory science practiced at the FDA.

Biogen gives Roche 'renewed confidence' in its own failed Alzheimer's drugs

Biogen turned heads around the industry last month with early data in which its plaque-destroying Alzheimer's treatment had a significant effect on patients' cognition, bucking a vexing trend for such antibodies. Among those paying close attention was Roche, which is now re-examining a pair of once-failed treatments.

Roche bets $555M on an Indian biotech's immuno-oncology drug

Roche inked a deal worth up to $555 million to work with India's Curadev Pharma on cancer treatments that use the body's immune system to combat tumors, expanding its trove of assets in one of the industry's hottest fields.

Roche, Novartis to halt marketing for unreimbursed cancer drugs in Australia

Swiss drugmakers Roche and Novartis Oncology have told Australia to go fly a kite if it expects a company to market a cancer drug in the country without Pharmaceutical Benefits Scheme coverage. The two companies announced their boycott intentions ahead of a Monday hearing by a panel of Australia's Senate.

ThromboGenics spins out Roche-rejected cancer drug

ThromboGenics is trying to give the TB-403 cancer drug Roche walked away from in 2012 a new lease of life. The arrangement sees ThromboGenics teaming up with life science research institute VIB to create a new biotech focused on shepherding the drug through clinical development.

Gilead's hep C drugs make it king of the hill in U.S. drug sales

The U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences, whose hep C drugs vaulted it to the top, according to  PMLiVE  based on sales info from GlobalData.

Roche's Ventana strikes companion diagnostic deal with Astellas Pharma

Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.

Roche hustles its PD-L1 'breakthrough' star into 11 late-stage trials

In the checkpoint receptors race, Bristol-Myers Squibb is out in front with the biggest and fastest effort, a comeback Merck is in hot pursuit and Roche/Genentech and AstraZeneca are following but still in the front of the pack.